Fierce Pharma
SEPTEMBER 25, 2024
Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. | Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to its $5.4 billion acquisition of Global Blood Therapeutics two years ago.
MedCity News
SEPTEMBER 25, 2024
The way venture capital firms invest in biotech startups has changed. Veteran VCs Chris Garabedian and Arjun Goyal offered their perspectives during a panel discussion at the World Medical Innovation Forum. The post Two Venture Investors Offer Their Takes on the State of Biotech Investing Today appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 25, 2024
Three months after Amgen revealed that Uplizna had aced a phase 3 trial in immunoglobulin G4-related disease (IgG4), the company said the anti-CD-19 antibody has excelled in a study against another | Three months after Amgen revealed that Uplizna had aced a phase 3 trial in IgG4, the company said the anti-CD-19 antibody has excelled in a study against another neurologic disorder, myasthenia gravis.
MedCity News
SEPTEMBER 25, 2024
The lack of consistent data standards poses a major barrier to the exchange of information across stakeholders. As providers and administrators struggle to identify the best next step to meet new standardization rules, they need a strategy tailored to the intricacies of their program, based on their specific data workflows — which might look vastly different state to state.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
SEPTEMBER 25, 2024
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial in first-line myeloma after struggling to enroll patients.
MedCity News
SEPTEMBER 25, 2024
Though chronic disease treatment is rapidly expanding, balancing the latest medication with proven initiatives can help employers manage rising healthcare costs wherever you fall on the GLP-1 coverage spectrum. The post Considering Covering GLP-1s? Here’s What You Need to Know appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 25, 2024
Qure.ai — which is headquartered in India — closed a $65 million Series D financing round. When asked whether the startup is thinking about a public exit anytime soon, CEO Prashant Warie said that for now, the company’s focusing is on continuing to build its market globally and “venturing deeper into meeting the healthcare challenges of the U.S.” The post Qure.AI Snags $65M to Expand Its Presence in US Market appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 25, 2024
As private equity firms reportedly place their bids, Sanofi may soon follow in the footsteps of GSK and Johnson & Johnson with the separation of its consumer health unit. | Sanofi has received two private equity offers for its consumer health business, which could be valued at 15 billion euros ($16.7 billion) or more, Bloomberg reported Tuesday, citing people close to the matter.
pharmaphorum
SEPTEMBER 25, 2024
Pfizer is voluntarily withdrawing its sickle cell drug Oxbryta after a review revealed an imbalance of deaths in clinical trials
MedCity News
SEPTEMBER 25, 2024
Centivo’s $75 million raise includes funding from new investors Cone Health Ventures and MemorialCare Innovation Fund, as well as existing investors B Capital, Cox Enterprises, F-Prime Capital, Ingleside Investors and Morgan Health. The post Centivo Snags $75M To Make Healthcare More Accessible and Affordable for Workers appeared first on MedCity News.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
SEPTEMBER 25, 2024
Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's semaglutide drugs for diabetes and obesity at a congressional hearing yesterday – but would not commit to reducing them. Jørgensen danced around the topic of price cuts, saying Novo Nordisk supported "anything that helps patients get access and affordability […] we will look into.
Pharmaceutical Technology
SEPTEMBER 25, 2024
The tracker, currently available via a pilot scheme, could save pharmacists hours by reducing patient queries.
pharmaphorum
SEPTEMBER 25, 2024
Flagship Pioneering-backed artificial intelligence startup Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.The wide-ranging deal, worth up to $1 billion, covers multiple targets and disease areas and focuses on the discovery and development of protein-based therapeutics using Generate's generative AI (genAI) platform.
Pharmaceutical Technology
SEPTEMBER 25, 2024
Some counterfeits contain bacteria and have high impurity levels or different chemical structures to Lilly's FDA-approved medicines.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
SEPTEMBER 25, 2024
Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug
PharmaTech
SEPTEMBER 25, 2024
FDA’s Darby Kozak provided commentary on the anniversary of the Drug Price Competition and Patent Term Restoration Act of 1984.
pharmaphorum
SEPTEMBER 25, 2024
Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.Vyznova (neltependocel, formerly AURN001) is the world's first allogeneic cell therapy for corneal endothelial disease, according to the Seattle, Washington-based company.
PharmaTech
SEPTEMBER 25, 2024
Two drugs, Miplyffa (arimoclomol) and Aqneursa (levacetylleucine), have been approved by FDA to treat neurological symptoms associated with Niemann-Pick disease, type C in adults and children.
Clarivate
SEPTEMBER 25, 2024
Wouldn’t it be great to find a single cure for every disease? A ‘magic bullet’ medicine that can cure a disease quickly and completely, [1] without deleterious side effects. [2] But by focusing on selective toxicity and seeking ‘magic bullet’ cures at the expense of other promising treatments, are we overlooking other important innovations? The first ‘magic bullet’ in medicine The underlying principles of translational research and precision medicine originate from the work of scientists such as
pharmaphorum
SEPTEMBER 25, 2024
Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to its highest level in a year and could lead to discussions with regulators about a route to market.
European Pharmaceutical Review
SEPTEMBER 25, 2024
This report delves into the latest developments impacting the pharmaceutical biologic drug sector today. Inside, articles explore current key topics including biosimilars, antibody drugs, manufacturing, drug delivery and vaccines. Stay up to date with the latest developments in biologics including articles on: Navigating the demanding biosimilar landscape and improving patient access to biologic therapies Preventing infectious diseases with innovative vaccine development Current trends and fut
Pharmacy Times
SEPTEMBER 25, 2024
Although Madabhushi said there are emerging tools for clinical decision support, he said there is a greater need for tools further downstream in the post-diagnosis stages.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Evolve Your Success
SEPTEMBER 25, 2024
Unlock the secrets to mastering medical sales and marketing in our latest episode featuring TJ Quigley, Marketing expert. TJ brings a wealth of knowledge about targeting emergency department doctors through precise messaging, the significance of measuring marketing outcomes, and the dynamic strategies his team employs based on real-time feedback. His insights into the role of digital marketing in the respiratory healthcare space are invaluable for anyone looking to elevate their marketing game.
Pharmacy Times
SEPTEMBER 25, 2024
Additional education can address ambivalence for patients and providers, which can start at the pharmacist level, as they are essential sources of information for patients.
Evolve Your Success
SEPTEMBER 25, 2024
Unlock the secrets to mastering medical sales and marketing in our latest episode featuring TJ Quigley, Marketing expert. TJ brings a wealth of knowledge about targeting emergency department doctors through precise messaging, the significance of measuring marketing outcomes, and the dynamic strategies his team employs based on real-time feedback. His insights into the role of digital marketing in the respiratory healthcare space are invaluable for anyone looking to elevate their marketing game.
Pharmaceutical Commerce
SEPTEMBER 25, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Arnon Lopes, head, customer experience, pharma & healthcare, JAS, discusses ways that IoT can support sustainable supply chains at LogiPharma USA in Boston.
European Pharmaceutical Review
SEPTEMBER 25, 2024
Researchers have demonstrated a novel approach that uses machine-learning aided UV absorbance spectroscopy to detect contamination during the manufacture of cell therapy products. Based on the findings, the cost-effective and non-invasive method provides a “rapid output (30 minutes) with minimal sample preparation and sample volume (<1mL)”. In their paper, the researchers stated that considering the limitations of current manufacturing processes, there is a need for sterility testing of cell
Pharmaceutical Technology
SEPTEMBER 25, 2024
This article explores the strategies that fill finish CDMOs use to effectively manage temperature-sensitive drug products during the fill finish process.
PharmExec
SEPTEMBER 25, 2024
The legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer's drug development, leading to securities litigation over allegedly misleading statements about trial results and commercialization efforts.
Pharmaceutical Technology
SEPTEMBER 25, 2024
The funds will advance Genespire’s gene therapy for methylmalonic acidemia, a group of rare metabolic disorders, to Phase I/II trials.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
340 
Let's personalize your content